金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01548 金斯瑞生物科技

休市中 06-12 16:08:21

13.020

+1.180

+9.97%

最高13.020	最低11.520	成交量6,775万
今开12.080	昨收11.840	日振幅12.67%
总市值284.88亿	流通市值284.88亿	总股本21.88亿
成交额8.33亿	换手率3.10%	流通股本21.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":13.02,"timestamp":1781251701006,"preClose":11.84,"halted":0,"volume":67745815,"delay":0,"changeRate":0.09966216216216214,"floatShares":2188000000,"shares":2188000000,"eps":-1.9261058652979666,"marketStatus":"休市中","change":1.18,"latestTime":"06-12 16:08:21","open":12.08,"high":13.02,"low":11.52,"amount":833482743,"amplitude":0.126689,"askPrice":13.03,"askSize":54000,"bidPrice":13.02,"bidSize":5050000,"shortable":3,"etf":0,"ttmEps":-1.9264741605610627,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1451404800000,"exchange":"SEHK","adjPreClose":11.84,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":3.3282297488584933,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548","defaultTab":"news","newsList":[{"id":"1173569654","title":"异动解读｜金斯瑞生物科技盘中下跌5.05%，CXO板块持续承压叠加美国对华生物医药投资限制担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1173569654","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173569654?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:05","pubTimestamp":1780974321,"startTime":"0","endTime":"0","summary":"6月9日，金斯瑞生物科技盘中下跌5.05%，报11.46港元/股，成交额9887.48万港元。消息面上，医药外包（CXO）概念股近日持续全线走弱，板块联动效应显著。此前一个交易日，药明生物跌超7%、药明合联跌超6%、康龙化成跌超6%，行业集体承压。与此同时，市场对美国拟限制甚至禁止对中国新药研发投资的政策担忧再度升温，进一步压制生物医药板块风险偏好。金斯瑞生物科技近期虽在股东大会上释放盈利改善及资本回报预期，但政策面不确定性与板块系统性抛压仍主导短期走势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182809006","title":"异动解读｜金斯瑞生物科技盘中下跌7.04%，医药外包概念股全线走弱板块承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1182809006","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182809006?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:01","pubTimestamp":1780902115,"startTime":"0","endTime":"0","summary":"6月8日，金斯瑞生物科技盘中下跌7.04%，报12.01港元/股，成交额1.55亿港元。消息面上，当日医药外包概念股全线走低，CXO板块集体承压。药明生物跌超7%、方达控股跌逾7%、药明合联跌超6%，板块联动效应显著加剧个股下行压力。港股大盘同步走弱，恒生科技指数下跌2.4%，市场风险偏好明显回落。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641105779","title":"医药外包概念股全线走低 金斯瑞生物科技(01548)跌7.43%、药明生物(02269)跌7.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2641105779","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641105779?lang=zh_cn&edition=full","pubTime":"2026-06-08 13:43","pubTimestamp":1780897412,"startTime":"0","endTime":"0","summary":"中邮证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983281","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","BK1521","BK1589","LU0516422366.SGD","BK1141","LU0051755006.USD","03759","LU0516422440.USD","HK0000306685.HKD","LU0516423091.SGD","HK0000320264.USD","LU0417516902.SGD","01548","LU0572944931.SGD","01521","LU0039217434.USD","LU2039709279.SGD","09939","06821","LU0326950275.SGD","LU1720050803.USD","BK1191","159938","LU0140636845.USD","02359","LU2242644610.SGD","LU3063872942.SGD","LU0417516738.SGD","LU0320764599.SGD","LU0348735423.USD","LU1688375341.USD","LU1880383366.USD","01873","LU0359201612.USD","02269","LU0307460666.USD","LU0856984785.SGD","LU0456827905.SGD","LU0516422952.EUR","LU2045819591.USD","LU1046422090.SGD","HK0000320223.HKD","SG9999002463.SGD","LU0348766576.USD","LU0348767384.USD","BK1574","LU0588546209.SGD","03347","BK1515","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165362","title":"金斯瑞生物科技(01548)授出合共1473.67万个限制性股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165362","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640165362?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:42","pubTimestamp":1780584169,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2026年6月4日，本公司向4名董事、本公司轮值首席执行官、若干雇员及一名服务提供者授出合共1473.67万个限制性股份单位，惟待接纳及须遵守2021年限制性股份单位计划的条款及条件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","HK0000320264.USD","BK1583","HK0000306701.USD","BK1141","HK0000306685.HKD","HK0000320223.HKD","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640972760","title":"港股收盘(06.03) | 恒指收跌1.56% 光通信概念逆市走强 油气股午后拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2640972760","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640972760?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:22","pubTimestamp":1780474925,"startTime":"0","endTime":"0","summary":"截至收盘，恒生指数跌1.56%或405.11点，报25633.21点，全日成交额3229.21亿港元；恒生国企指数跌1.9%，报8596.59点；恒生科技指数跌2.74%，报5056.97点。截至收盘，跌3.16%，报466.4港元，成交额229.95亿港元，拖累恒指61.39点。隔夜美股市场光通信龙头迈威尔科技股价大涨超30%。截至收盘，跌10.25%，报17.95港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","LU0588546209.SGD","HHImain","02833","LU2039709279.SGD","HK0000320264.USD","BK1202","HK0000306701.USD","SG9999006597.SGD","09115","03115","BK1576","07200","LU1813983027.USD","01888","BK1240","06869","BK1583","HSI","MCHmain","MHImain","LU0314109678.HKD","159195","HSImain","00568","VXUS","02800","LU1328277881.USD","BK1170","LU2187417386.USD","01548","BK1506","LU0307460666.USD","BK4588","82800","LU2351347302.SGD","BK1141","513600","07500","03419","BK1523","HK0000320223.HKD","07300","LU2929501877.USD","02553","BK1149","83115","06166","BK4585","03037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640927867","title":"港股异动 | 金斯瑞生物科技(01548)高开近15% 传奇生物披露治疗淋巴瘤初步临床数据显示积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2640927867","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640927867?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:23","pubTimestamp":1780449806,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技高开近15%，截至发稿，涨14.99%，报13.96港元，成交额617.03万港元。6月2日晚，金斯瑞生物科技公布，美国上市联营公司传奇生物披露在研体内CD19/CD20双靶点CAR-T细胞疗法LB2501在复发或难治性B细胞非霍奇金淋巴瘤患者中的初步临床数据。通过在患者体内直接生成CAR-T细胞，该方法有望简化治疗流程，并提升传统CAR-T细胞疗法难以覆盖患者的可及性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4d1d21998b91aebef2a8df95d5795877","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK4585","HK0000306701.USD","BK4139","HK0000320223.HKD","BK1583","BK1576","BK4588","HK0000306685.HKD","VXUS","01548","BK1141","HK0000320264.USD","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147210091","title":"金斯瑞生物科技更新5月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1147210091","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147210091?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:12","pubTimestamp":1780387937,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技股份有限公司于2026年6月2日发布截至2026年5月31日的股份变动月报表。公告显示，公司法定股本维持为50亿美元，与上月保持一致。公司确认已满足香港联交所对公众持股比例的相关要求。报告期内未出现注銷或库藏股变动，总股本相较上月小幅增长，库存股份数目为零。公司表示将持续遵守香港联交所《上市规则》及相关法律法规，保持规范运作。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968362","title":"金斯瑞生物科技(01548)：传奇于2026年ASCO大会公布LB2102治疗实体瘤的首次人体研究结果及CARVYKTI®治疗多发性骨髓瘤的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968362","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640968362?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:52","pubTimestamp":1780325527,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，公司联营公司传奇生物科技股份有限公司(“传奇”，其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)于2026年6月1日(纽约时间)(2026年6月1日香港交易时段后)已向美国证券交易委员会提交6-K表格，并发布新闻稿公布其靶向DLL3的在研CAR-T细胞疗法LB2102在复发或难治性小细胞肺癌(SCLC)或大细胞神经内分泌癌(LCNEC)患者中的首次人体试验数据，同时亦公布了来自 CARTITUDE 项目的最新分析 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金斯瑞生物科技(01548)：传奇于2026年ASCO大会公布LB2102治疗实体瘤的首次人体研究结果及CARVYKTI®治疗多发性骨髓瘤的最新数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000306701.USD","BK1583","HK0000320223.HKD","HK0000320264.USD","BK1141","BK1576","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179476257","title":"异动解读 | 金斯瑞生物科技盘中大跌5.26%，ASCO利好消化叠加板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1179476257","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179476257?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:08","pubTimestamp":1780283329,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中出现大幅下跌，跌幅达5.26%，引发市场关注。消息面上，公司联营公司传奇生物此前在ASCO年会上发布了多项研究成果，包括靶向DLL3的CAR-T疗法LB2102的临床数据及CARVYKTI新数据。这一利好消息曾在之前推动股价显著上涨，目前市场正处于对该利好的持续消化阶段，部分投资者选择获利了结。此外，港股通资金此前连续出现大额净流出，机构借利好减持的行为也引发了市场的警惕。从行业层面看，今日生命科学工具和服务板块整体表现疲软，多只相关个股下跌，板块的联动效应进一步加剧了金斯瑞生物科技的下行压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151113165","title":"异动解读｜金斯瑞生物科技盘中下跌5.19%，ASCO利好持续消化叠加行业板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1151113165","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151113165?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:08","pubTimestamp":1780283290,"startTime":"0","endTime":"0","summary":"6月1日，金斯瑞生物科技盘中下跌5.19%，报12.97港元/股，成交额1.15亿港元。消息面上，公司联营公司传奇生物此前于ASCO年会发布多项研究成果，该利好已于5月27日推动股价大涨逾5%，随后连续多个交易日出现获利了结。此外，港股通此前连续出现大额净流出，机构借利好减持引发市场警惕。行业层面，生命科学工具和服务板块今日整体承压，英矽智能跌7.12%、晶泰控股跌2.67%、药明合联跌2.0%，板块联动效应进一步加剧个股下行压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113295290","title":"异动解读 | 金斯瑞生物科技盘中大跌5.01%，ASCO利好兑现后获利了结叠加行业板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1113295290","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113295290?lang=zh_cn&edition=full","pubTime":"2026-05-28 11:28","pubTimestamp":1779938935,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中大跌5.01%，引发了市场关注。消息面上，此次股价回落主要受到多重因素影响。今日盘中下跌，可能反映了市场在利好信息被充分消化后的获利了结行为。此外，从行业层面看，整个生命科学工具与服务板块今日普遍承压，相关同业公司股价均出现不同程度下跌，板块的联动下跌效应进一步加剧了金斯瑞生物科技个股的下行压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167673594","title":"异动解读｜金斯瑞生物科技盘中下跌5.01%，前日ASCO利好消化后回落叠加行业整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1167673594","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167673594?lang=zh_cn&edition=full","pubTime":"2026-05-28 11:28","pubTimestamp":1779938885,"startTime":"0","endTime":"0","summary":"5月28日，金斯瑞生物科技盘中下跌5.01%，报14.4港元/股，成交额1.01亿港元。消息面上，公司联营公司传奇生物于ASCO年会发布多项研究成果，该利好已于前一交易日推动股价大涨逾5%。当前股价回落或系市场对利好兑现后的获利了结。此外，港股通此前连续多日出现大额净流出，机构借利好减持的声音引发市场警惕。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638527636","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 近日联营传奇生物多项研究成果于2026年ASCO年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2638527636","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638527636?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:57","pubTimestamp":1779847023,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技涨超5%，截至发稿，涨5.35%，报13.98港元，成交额5063.58万港元。消息面上，近日，金斯瑞生物科技发布公告，公司联营公司传奇生物科技股份有限公司已于2026年5月21日向美国证券交易委员会提交6-K表格并发布新闻稿，宣布在2026年美国临床肿瘤学会年会上发表多项研究成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK4585","VXUS","BK4139","LEGN","BK4505","BK1583","HK0000320223.HKD","BK1141","BK1576","HK0000320264.USD","HK0000306701.USD","BK4588","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199077169","title":"异动解读 | 传奇生物ASCO年会发布新数据，金斯瑞生物科技盘中大涨5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199077169","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199077169?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:54","pubTimestamp":1779846865,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中大涨5.57%，引起了市场的广泛关注。消息面上，其联营公司传奇生物将在美国临床肿瘤学会（ASCO）年会上发表多项研究成果，其中包括靶向DLL3的CAR-T疗法LB2102的1期临床初步资料，用于治疗复发或难治性小细胞肺癌及大细胞神经内分泌癌，同时还将公布CARVYKTI（西达基奥仑赛）的新数据。CAR-T疗法向实体瘤领域的拓展为公司打开了新的增长想象空间。此外，市场此前对金斯瑞估值倒挂（总市值低于所持传奇生物股权价值）的讨论，也在此次利好消息下推动了短期情绪的修复，共同提振了股价。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121948378","title":"异动解读｜金斯瑞生物科技盘中上涨5.12%，传奇生物ASCO年会多项研究成果发布提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1121948378","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121948378?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:48","pubTimestamp":1779846508,"startTime":"0","endTime":"0","summary":"5月27日，金斯瑞生物科技盘中上涨5.12%，报14.0港元/股，成交额4290.77万港元。消息面上，公司此前公告其联营公司传奇生物将在ASCO年会上发表多项研究成果，其中包括LB2102的1期临床初步资料——这是一款靶向DLL3的CAR-T疗法，用于治疗复发或难治性小细胞肺癌及大细胞神经内分泌癌，同时还将公布CARVYKTI的新数据。CAR-T疗法向实体瘤领域的拓展为公司打开新增长想象空间，叠加市场此前对金斯瑞估值倒挂的讨论，短期情绪修复推动股价反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637788363","title":"金斯瑞生物科技(01548)：传奇在2026年美国临床肿瘤学会年会上发布多项研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2637788363","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637788363?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:17","pubTimestamp":1779409052,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，公司联营公司传奇生物科技股份有限公司已于2026年5月21日向美国证券交易委员会提交6-K表格并发布新闻稿，宣布在2026年美国临床肿瘤学会年会上发表多项研究成果。其中一项快速口头报告将重点展示LB2102 的1期临床初步资料，这是一款在研的靶向DLL3的CAR-T 疗法，用于治疗复发或难治性小细胞肺癌及大细胞神经内分泌癌，同时，还将公布 CARVYKTI的新数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK1141","HK0000320223.HKD","BK1576","01548","HK0000320264.USD","HK0000306701.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885146","title":"生物医药板块盘初普涨 药明合联(02268)涨5.24%、百济神州(06160)涨2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885146","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636885146?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:46","pubTimestamp":1779155169,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普涨，截至发稿，药明合联 涨5.24%，科伦博泰生物涨4.01%，百济神州涨2.17%，诺诚健华涨2.00%，药明生物涨1.58%，康诺亚-B涨1.35%，金斯瑞生物科技涨1.12%。消息面上，中邮证券研究表示，26年有望迎来BD和重点项目数据读出的双重催化，国产创新药全球性竞争力提升逻辑不断强化。建议关注确定性高、BD预期扰动相对小的标的。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426308.USD","LU1303224171.USD","BK1574","BK1589","09969","688235","LU1242518931.SGD","06160","01548","LU0181495838.USD","LU0708995583.HKD","LU1719994722.HKD","BK1583","BK4581","ONC","LU0348825331.USD","BK1588","LU0417516902.SGD","LU1770034418.SGD","XBI","LU0456846285.SGD","399441","LU1688375341.USD","LU0359202008.SGD","LU0039217434.USD","SG9999002562.SGD","LU0052750758.USD","LU1251922891.USD","HK0000320264.USD","IE00B0JY6N72.USD","LU0516422440.USD","BK1141","BK4588","LU0359201612.USD","LU0417516738.SGD","LU0043850808.USD","LU0516422366.SGD","LU3063872942.SGD","LU0320764599.SGD","LU0588546209.SGD","02268","HK0000306701.USD","LU0307460666.USD","06990","02269","BK1576","161726","BK1161","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02285","00136","02197","00169","06963","01357","00719","06609","01783","02252","01440","06969","02618","02172","02158","02306","09888","00909","81024","06160","01548","09688","00013","06996","09858","03692","06660","03888","02256","02171","02096","01060","01952","06186","02013","06060","02192","06049","09626","09992","01951","09699","00762","02126","01024","02276","00772","03700","01905","01833"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154148284","title":"异动解读 | 礼来收购提振板块情绪，金斯瑞生物科技盘中大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154148284","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154148284?lang=zh_cn&edition=full","pubTime":"2026-05-13 09:39","pubTimestamp":1778636349,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中大涨5.45%，引起了市场的广泛关注。消息面上，此次股价上涨主要受到多重利好因素推动。首先，礼来公司此前以70亿美元收购生物技术公司Kelonia，这一重大交易持续提振了整个细胞治疗板块的市场情绪。其次，金斯瑞联营公司传奇生物的核心产品CARVYKTI一季度销售额表现强劲，达到约5.97亿美元，同比增长61.8%，显示出坚实的基本面。此外，多家投资机构近期维持了对金斯瑞生物科技的积极评级。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635227658","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 联营传奇生物一季度亏损收窄、CARVYKTI®净销售额增六成","url":"https://stock-news.laohu8.com/highlight/detail?id=2635227658","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635227658?lang=zh_cn&edition=full","pubTime":"2026-05-13 09:34","pubTimestamp":1778636055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)涨超5%，截至发稿，涨5.03%，报15.23港元，成交额2969.6万港元。消息面上，金斯瑞生物科技联营传奇生物隔夜股价大涨超10%。传奇生物昨日公布了2026年第一季度未经审计的财务业绩及公司主要重点，与2025年第一季度相比，CARVYKTI®在2026年第一季度的净销售额增长62%，达到约5.97亿美元。其中美国市场净销售额增长36%，美国以外的市场净销售额增长222%。此外，公司截至2026年3月31日止三个月的净亏损收窄至5430万美元，而去年同期净亏损为1.010亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK4585","VXUS","BK4139","LEGN","BK4505","BK1583","HK0000320223.HKD","BK1141","BK1576","HK0000320264.USD","HK0000306701.USD","BK4588","01548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":0.0077},{"period":"1month","weight":-0.1179},{"period":"3month","weight":0.174},{"period":"6month","weight":-0.0356},{"period":"1year","weight":-0.2323},{"period":"ytd","weight":0.0483}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.000341},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075475},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.060575},{"month":4,"riseRate":0.545455,"avgChangeRate":0.057883},{"month":5,"riseRate":0.454545,"avgChangeRate":0.061694},{"month":6,"riseRate":0.545455,"avgChangeRate":0.036127},{"month":7,"riseRate":0.6,"avgChangeRate":0.075818},{"month":8,"riseRate":0.4,"avgChangeRate":0.101263},{"month":9,"riseRate":0.4,"avgChangeRate":-0.071937},{"month":10,"riseRate":0.6,"avgChangeRate":0.095918},{"month":11,"riseRate":0.6,"avgChangeRate":0.045101},{"month":12,"riseRate":0.3,"avgChangeRate":0.042047}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}